Using data from the Surveillance, Epidemiology, and End Results (SEER) Program based at the National Cancer Institute in the US, conditional survival rates are reported for 1,988 Ewing Sarcoma patients diagnosed durin...Using data from the Surveillance, Epidemiology, and End Results (SEER) Program based at the National Cancer Institute in the US, conditional survival rates are reported for 1,988 Ewing Sarcoma patients diagnosed during the period 2000-2015. These patients represent the experience of 26.5% of the US population. Specifically, 5-year conditional relative survival rates are calculated for these patients for the first eight years subsequent to diagnosis of their cancer by Extent of Disease (EOD) (Localized, Regional, and Distant as coded by the SEER Program), gender, and age (<18, 18 - 34, and 35+). Findings include showing how the conditional survival rate patterns improve over time and that there are differences by gender, age, and EOD.展开更多
Background: Conditional survival(CS) has been established as a clinically relevant prognostic factor for cancer survivors, and the CS in gallbladder(GB) cancer has not yet been fully evaluated. In this study, we evalu...Background: Conditional survival(CS) has been established as a clinically relevant prognostic factor for cancer survivors, and the CS in gallbladder(GB) cancer has not yet been fully evaluated. In this study, we evaluated the cancerspecific CS rate and cancer-specific survival(CSS) rate in patients with GB cancer at multiple time points and investigated prognostic factors which affect cancer-specific CS rate to provide more accurate survival information.Methods: Between 2004 and 2013, a total of 9760 patients with GB cancer were identified from the Surveillance,Epidemiology, and End Results(SEER) data. The 3-year cancer-specific CS rate was calculated using the covariateadjusted survival function in the Cox model for each year since diagnosis, and the results were analyzed together with the adjusted CSS rates at the same time points. Cox proportional hazards regression was performed to ascertain the individual contribution of factors associated with CSS rate at diagnosis and cancer-specific CS rates at 1,3, and 5 years after diagnosis.Results: The adjusted 5-year CSS rate was 26.1 %. The adjusted 3-year cancer-specific CS rates at 1,2,3,4, and 5 years after diagnosis were 55.5,72.2,81.5,86.8, and 90.5%, respectively. At the time of diagnosis, age, race, histology, grade,T, N, and M categories, surgery, radiotherapy, insurance status, and marriage status were significant prognostic factors of CSS. Five years after diagnosis, however,T and M categories were significant prognostic factors for survivors(P = 0.007 and P = 0.009, respectively), whereas surgery and radiotherapy were not.Conclusions: T and M categories were significant prognostic factors even 5 years after the initial diagnosis, whereas local treatments at the time of diagnosis were not, suggesting that patients with GB cancer at high risks might need further adjuvant therapy after primary treatments. The combined analysis of CSS and cancer-specific CS rates offered more accurate survival information for patients who have already survived a certain perio展开更多
文摘Using data from the Surveillance, Epidemiology, and End Results (SEER) Program based at the National Cancer Institute in the US, conditional survival rates are reported for 1,988 Ewing Sarcoma patients diagnosed during the period 2000-2015. These patients represent the experience of 26.5% of the US population. Specifically, 5-year conditional relative survival rates are calculated for these patients for the first eight years subsequent to diagnosis of their cancer by Extent of Disease (EOD) (Localized, Regional, and Distant as coded by the SEER Program), gender, and age (<18, 18 - 34, and 35+). Findings include showing how the conditional survival rate patterns improve over time and that there are differences by gender, age, and EOD.
文摘Background: Conditional survival(CS) has been established as a clinically relevant prognostic factor for cancer survivors, and the CS in gallbladder(GB) cancer has not yet been fully evaluated. In this study, we evaluated the cancerspecific CS rate and cancer-specific survival(CSS) rate in patients with GB cancer at multiple time points and investigated prognostic factors which affect cancer-specific CS rate to provide more accurate survival information.Methods: Between 2004 and 2013, a total of 9760 patients with GB cancer were identified from the Surveillance,Epidemiology, and End Results(SEER) data. The 3-year cancer-specific CS rate was calculated using the covariateadjusted survival function in the Cox model for each year since diagnosis, and the results were analyzed together with the adjusted CSS rates at the same time points. Cox proportional hazards regression was performed to ascertain the individual contribution of factors associated with CSS rate at diagnosis and cancer-specific CS rates at 1,3, and 5 years after diagnosis.Results: The adjusted 5-year CSS rate was 26.1 %. The adjusted 3-year cancer-specific CS rates at 1,2,3,4, and 5 years after diagnosis were 55.5,72.2,81.5,86.8, and 90.5%, respectively. At the time of diagnosis, age, race, histology, grade,T, N, and M categories, surgery, radiotherapy, insurance status, and marriage status were significant prognostic factors of CSS. Five years after diagnosis, however,T and M categories were significant prognostic factors for survivors(P = 0.007 and P = 0.009, respectively), whereas surgery and radiotherapy were not.Conclusions: T and M categories were significant prognostic factors even 5 years after the initial diagnosis, whereas local treatments at the time of diagnosis were not, suggesting that patients with GB cancer at high risks might need further adjuvant therapy after primary treatments. The combined analysis of CSS and cancer-specific CS rates offered more accurate survival information for patients who have already survived a certain perio
